Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

To identify potential pharmacodynamic biomarkers to guide dose selection in clinical trials using anti-interferon-alpha (IFN-α) monoclonal antibody (mAb) therapy for systemic lupus erythematosus (SLE), we used an Affymetrix human genome array platform and identified 110 IFN-α/β-inducible transcripts...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Yihong, Higgs, Brandon W., Morehouse, Chris, de los Reyes, Melissa, Trigona, Wendy, Brohawn, Philip, White, Wendy, Zhang, Jianliang, White, Barbara, Coyle, Anthony J., Kiener, Peter A., Jallal, Bahija
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950308/
https://www.ncbi.nlm.nih.gov/pubmed/20948567
http://dx.doi.org/10.4061/2009/374312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950308/
https://www.ncbi.nlm.nih.gov/pubmed/20948567
http://dx.doi.org/10.4061/2009/374312

Ejemplares similares